Targeting of the pathological secretion of VEGF from RPE cells with a multi-RTK inhibitor may thus be a potential therapeutic approach to the resolution of sterile inflammation and angiogenesis associated with retinal diseases. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.